To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
19 Current news about the topic quarterly reportsrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Merck generated strong organic sales growth and benefited from positive foreign exchange effects in the third quarter of 2019. EBITDA pre increased even more strongly than net sales in the three-month period from July to September. Following the closing of the Versum Materials (Versum) ...
Agreements signed to divest Currenta and Animal Health
Bayer has made progress in all key areas and is on track both operationally and strategically. “Bayer had a successful third quarter,” Werner Baumann, Chairman of the Board of Management, said on Wednesday during the news conference call on the quarterly figures. “We increased the Group’s sales ...
Sartorius performed dynamically in the third quarter as well, achieving double-digit growth rates in sales revenue, order intake and earnings in the first nine months. “Sartorius achieved significant double-digit growth rates in sales revenue and earnings for the first nine months of the year as ...
Net sales growth thanks to organic performance
Merck generated strong net sales growth in the second quarter of 2019, primarily on an organic basis. EBITDA pre grew very strongly and was also driven by organic performance. Merck confirmed its full-year forecast for 2019. “We achieved sales growth in all business sectors and regions. The jump ...
Business in Asia drives Group organic growth
Merck significantly increased net sales in the first quarter of 2019, primarily on an organic basis. By contrast, EBITDA pre saw a slight organic decline and was adversely impacted by the absence of positive one-time effects from the previous year. Merck confirmed its full-year forecast for ...
The Bayer Group achieved a strong start to the year in its operational business. “A major factor in this success was our agriculture business, while Pharmaceuticals also delivered encouraging performance,” said Werner Baumann, Chairman of the Board of Management, on Thursday when presenting the ...
Sartorius started off fiscal 2019 with substantial double-digit growth in order intake, sales revenue and earnings. Consolidated first-quarter sales revenue rose in constant currencies by 16.8% to 435.7 million reported: 19.4%); order intake increased 16.6% to 482.8 million euros (reported: ...
Strong organic sales growth impacted by negative exchange rate effects
Merck generated very strong organic sales growth in the third quarter of 2018. However, this was impacted by negative exchange rate effects. Despite organic growth, EBITDA pre of the Group also declined in comparison with the year-earlier quarter owing to strong negative foreign exchange effects. ...
Growth dynamics of the Lab Products & Services Division impacted by softer European demand
Sartorius continued on the growth track, with double-digit gains in sales revenue and earnings. “In the first nine months of 2018, Sartorius achieved excellent organic growth,” said Dr. Joachim Kreuzburg, Chief Executive Officer. “This applies particularly to the Bioprocess Solutions Division, ...
Group sales and earnings increase
Bayer successfully completed the biggest acquisition in its history in the second quarter of 2018, while operational performance improved, even without taking into account the newly acquired Monsanto business. Sales advanced at three of the four segments on a currency- and portfolio-adjusted ...